ZA982523B - Di-aryl ethers and their derivatives as anti-cancer agents. - Google Patents
Di-aryl ethers and their derivatives as anti-cancer agents.Info
- Publication number
- ZA982523B ZA982523B ZA9802523A ZA982523A ZA982523B ZA 982523 B ZA982523 B ZA 982523B ZA 9802523 A ZA9802523 A ZA 9802523A ZA 982523 A ZA982523 A ZA 982523A ZA 982523 B ZA982523 B ZA 982523B
- Authority
- ZA
- South Africa
- Prior art keywords
- derivatives
- cancer agents
- aryl ethers
- ethers
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4167997P | 1997-03-26 | 1997-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA982523B true ZA982523B (en) | 1999-10-04 |
Family
ID=21917767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9802523A ZA982523B (en) | 1997-03-26 | 1998-03-25 | Di-aryl ethers and their derivatives as anti-cancer agents. |
Country Status (8)
Country | Link |
---|---|
US (1) | US6169104B1 (ja) |
EP (1) | EP1003498A4 (ja) |
JP (1) | JP2001518935A (ja) |
AU (1) | AU741382B2 (ja) |
CA (1) | CA2285530A1 (ja) |
IL (1) | IL132029A0 (ja) |
WO (1) | WO1998042328A1 (ja) |
ZA (1) | ZA982523B (ja) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6433012B1 (en) * | 1998-03-25 | 2002-08-13 | Large Scale Biology Corp. | Method for inhibiting inflammatory disease |
EP1087785A2 (en) * | 1998-06-15 | 2001-04-04 | Arch Development Corporation | Combination of radiotherapy and anti-angiogenic factors |
US6326402B1 (en) | 1998-08-12 | 2001-12-04 | Octamer, Inc. | Methods for treating viral infections using a compound capable of inhibiting microtubules |
US20040229960A1 (en) * | 2001-07-13 | 2004-11-18 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
SG164368A1 (en) * | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
AU2007354301A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with PARP inhibitors |
AU2007292306A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
US7538252B2 (en) * | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
EP2059802A4 (en) * | 2006-09-05 | 2010-09-08 | Bipar Sciences Inc | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF |
EP2059498A4 (en) * | 2006-09-05 | 2011-01-12 | Bipar Sciences Inc | TREATMENT OF CANCER |
JP2011500684A (ja) * | 2007-10-19 | 2011-01-06 | バイパー サイエンシズ,インコーポレイティド | ベンゾピロン系parp阻害剤を用いる癌の処置方法および組成物 |
AU2008321128A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
NZ586123A (en) * | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors |
JP5302328B2 (ja) | 2007-11-21 | 2013-10-02 | オキシジーン, インコーポレイテッド | 造血性新生物を治療するための方法 |
RU2010128107A (ru) * | 2007-12-07 | 2012-01-20 | Байпар Сайенсиз, Инк. (Us) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp |
GB0725214D0 (en) * | 2007-12-24 | 2008-02-06 | Karobio Ab | Pharmaceutical compounds |
AU2009212401A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating PARP-mediated diseases |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
CA2905509A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Hsp90-targeted cardiac imaging and therapy |
US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
WO2017031157A1 (en) | 2015-08-18 | 2017-02-23 | Mateon Therapeutics, Inc. | Use of vdas to enhance immunomodulating therapies against tumors |
WO2017158190A1 (en) | 2016-03-17 | 2017-09-21 | Ecole polytechnique fédérale de Lausanne (EPFL) | Enhancers of notch signaling and their use in the treatment of cancers and malignancies medicable by upregulation of notch |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
AU2017388496A1 (en) | 2016-12-27 | 2019-07-18 | Daiichi Sankyo Company, Limited | Pyrimidine derivative |
WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
WO2018237327A1 (en) | 2017-06-22 | 2018-12-27 | Triact Therapeutics, Inc. | METHODS OF TREATING GLIOBLASTOMA |
US11628144B2 (en) | 2017-09-29 | 2023-04-18 | Triact Therapeutics, Inc. | Iniparib formulations and uses thereof |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
WO2020039092A2 (en) * | 2018-08-24 | 2020-02-27 | Xeniopro GmbH | Novel aromatic molecules |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
US20220305048A1 (en) | 2019-08-26 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
US12030888B2 (en) | 2021-02-24 | 2024-07-09 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5284864A (en) | 1991-09-23 | 1994-02-08 | Florida State University | Butenyl substituted taxanes and pharmaceutical compositions containing them |
US5430062A (en) | 1992-05-21 | 1995-07-04 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
AU4090093A (en) * | 1992-05-29 | 1993-12-30 | Yamanouchi Pharmaceutical Co., Ltd. | Medicine containing benzoic acid derivative and novel benzoic acid derivative |
US5356928A (en) | 1992-11-06 | 1994-10-18 | Hauser Chemical Research, Inc. | Cytotoxic agents |
US5504074A (en) | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
US5571822A (en) | 1994-09-30 | 1996-11-05 | The University Of North Carolina At Chapel Hill | Antitumor compounds |
US5736576A (en) * | 1996-06-04 | 1998-04-07 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
-
1998
- 1998-03-25 JP JP54601098A patent/JP2001518935A/ja active Pending
- 1998-03-25 US US09/047,945 patent/US6169104B1/en not_active Expired - Lifetime
- 1998-03-25 AU AU65888/98A patent/AU741382B2/en not_active Ceased
- 1998-03-25 EP EP98912089A patent/EP1003498A4/en not_active Withdrawn
- 1998-03-25 CA CA002285530A patent/CA2285530A1/en not_active Abandoned
- 1998-03-25 ZA ZA9802523A patent/ZA982523B/xx unknown
- 1998-03-25 IL IL13202998A patent/IL132029A0/xx unknown
- 1998-03-25 WO PCT/US1998/006037 patent/WO1998042328A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1003498A4 (en) | 2004-07-14 |
US6169104B1 (en) | 2001-01-02 |
AU741382B2 (en) | 2001-11-29 |
EP1003498A1 (en) | 2000-05-31 |
AU6588898A (en) | 1998-10-20 |
JP2001518935A (ja) | 2001-10-16 |
IL132029A0 (en) | 2001-03-19 |
CA2285530A1 (en) | 1998-10-01 |
WO1998042328A1 (en) | 1998-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA982523B (en) | Di-aryl ethers and their derivatives as anti-cancer agents. | |
ZA987037B (en) | Benzylidene-1-3-dihydro-indol-2-one derivatives having anti-cancer activity. | |
MXPA02001508A (es) | Derivados de arilmetil-carbonilamino-tiazol y sus usos como agentes antitumorales. | |
ZA9811339B (en) | Benzamidine derivatives. | |
EP1021972A4 (en) | WRITING DESK | |
AU4133096A (en) | Taxoid derivatives, their preparation and their use as antitumor agents | |
HK1027957A1 (en) | Pharmaceutical composition. | |
ZA981029B (en) | Pharmaceutical agents. | |
IL123013A (en) | Substituted imidazoles having biphenylsulfonyl substitution, and pharmaceutical compositions comprising them | |
ZA200104280B (en) | Pharmaceutical combination preparations. | |
AU8695698A (en) | Pharmacologic drug combination in vagal-induced asystole | |
HUP0000762A3 (en) | 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines, and pharmaceutical compositions containing them | |
ZA989680B (en) | Pharmaceutical composition. | |
HUP9802132A3 (en) | Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them | |
HK1022853A1 (en) | Pharmaceutical compositions. | |
GB0001794D0 (en) | Amphiphilic polysaccharide derivatives | |
ZA987392B (en) | Pharmaceutical composition. | |
HUP9802590A3 (en) | Indan-, benzothiophene-, benzofuran- and indolesulfonamide derivatives, their use and pharmaceutical compositions containing them | |
ZA989571B (en) | 2-Substituted 1,2-Benzoisonthiazole derivatives, their preparation and use. | |
ZA98306B (en) | Anti-cancer agents. | |
HUP9902883A3 (en) | Bis/acridinecarboxamide/ and bis/phenazinecarboxamide/ derivatives as antitumour agents, preparation and use thereof | |
CA85024S (en) | Desk | |
AU2306595A (en) | Dihydrodibenzo(de,h)isoquinolines derivatives and their use as anti-cancer agents | |
HUP0004132A3 (en) | Rapidly soluble drug composition | |
HUP0002166A3 (en) | 5-naphthalen-1-yl-1,3-dioxane derivatives and pharmaceutical compositions thereof |